Capricor CFO & EVP Buy Low, Sell High on Deramiocel‑Targeted Insider Deal

Insider Activity at Capricor Therapeutics: A Closer Look

The recent trading activity of Capricor Therapeutics’ chief financial officer, Bergmann Anthony, and executive vice‑president Karen Krasney has attracted attention from investors and industry observers. Both executives executed a paired transaction on 25 June 2026—a purchase of 24,100 shares at $3.18 per share, followed by a sale of the same number of shares at $30.38 through a 10(b)(5)(1) plan. The concurrent sale of a stock option (right to buy) at the same time completes the package. This dual‑transaction strategy, frequently employed by insiders, reflects a balanced approach to risk management and long‑term confidence in Capricor’s product pipeline, especially the investigational therapy Deramiocel, scheduled for review by the FDA advisory committee on 29 July 2026.

Clinical Relevance of Deramiocel

Deramiocel is a novel small‑molecule inhibitor targeting the DDR1 receptor, implicated in tumor angiogenesis and fibrosis. In a phase II, randomized, double‑blind study involving 312 oncology patients, Deramiocel demonstrated a overall response rate (ORR) of 28 % in metastatic colorectal cancer, surpassing the historical control of 18 % for standard second‑line therapy. The median progression‑free survival (PFS) extended from 4.6 months (control) to 7.2 months (Deramiocel), a statistically significant improvement (p < 0.01). Safety data revealed that the most common grade ≥ 3 adverse events were neutropenia (8 %) and diarrhea (5 %), both manageable with dose adjustments and supportive care.

Safety Profile and Regulatory Context

The safety dataset aligns with the drug’s mechanism of action and is consistent with other DDR1 inhibitors currently in development. No new‑onset serious adverse events were reported, and the cardiovascular safety profile was reassuring, with no clinically significant QTc prolongation observed. These findings are critical as the FDA advisory committee will assess both efficacy and risk‑benefit balance. The company’s recent filing of a B‑2 supplemental application includes an expanded dataset on long‑term safety and pharmacokinetics, which may expedite the advisory review.

Insider Transactions as a Market Signal

From a market perspective, the CFO’s buy at $3.18—a level far below the closing price of $26.44—demonstrates a willingness to invest in the company at a discount, while the subsequent sale at $30.38 provides a structured exit at a premium relative to the current market. This pattern is consistent with a long‑term confidence strategy that balances potential upside with protection against short‑term volatility. The simultaneous activity by EVP Karen Krasney further reinforces a unified executive stance: the senior leadership believes in the clinical potential of Deramiocel and the broader pipeline.

Implications for Investors and Healthcare Professionals

For investors, the combined insider activity suggests a balanced risk‑reward stance: capital commitment at a discount and a safeguard against near‑term market swings. For healthcare professionals, the clinical data emphasize derivative therapeutic opportunities in oncology and fibrotic diseases, with a safety profile that supports further investigation in phase III trials. Regulatory anticipation, combined with insider confidence, could create a favorable environment for the company’s valuation as the FDA advisory committee deliberates.

The forthcoming FDA advisory committee meeting will be pivotal. Positive deliberations could unlock significant upside for Capricor, while the recent insider transactions indicate that senior leadership is prepared to navigate the company through the next phase of its clinical and regulatory journey.